Leerink Raises Price Target as Roivant (ROIV) Accelerates Drug Development Pipeline

Roivant Sciences Ltd. (NASDAQ:ROIV) ranks among the best stocks under $25 to buy now. Following the company’s analyst meeting on December 11, Leerink Partners boosted its price target for Roivant Sciences Ltd. (NASDAQ:ROIV) to $32 from $29, keeping an Outperform rating on the company’s shares. The firm highlighted lower estimated operational expenses in the years ahead than previously modeled, resulting in reduced expected losses and significant profitability beginning in fiscal year 2029.

By the end of 2028, Roivant’s “Next 36 Month vision” anticipates at least three commercial launches, four or more NDA/BLA submissions, no less than eight crucial readouts, and at least three proof-of-concept evaluations.

Roivant Sciences Ltd. (NASDAQ:ROIV) has also advanced the development schedules for its primary therapeutic candidates, including brepocitinib, with a New Drug Application filing for dermatomyositis slated in early 2026 along with a possible commercial launch in early 2027. Furthermore, the Phase III trial for brepocitinib in non-infectious uveitis has reached full enrollment ahead of time, with topline results expected in the second half of 2026.

Roivant Sciences Ltd. (NASDAQ:ROIV) is a clinical-stage biopharmaceutical company that discovers, develops, and commercializes medicines and technologies. Its clinical product candidates include IMVT-1402, an antibody that targets the neonatal Fc receptor for the treatment of Graves’ disease and difficult-to-treat rheumatoid arthritis.

While we acknowledge the potential of ROIV to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than ROIV and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 10 Best Magic Formula Stocks for 2025 and 10 Best Retirement Stocks to Buy According to Hedge Funds.

Disclosure: None. This article is originally published at Insider Monkey.